BR9611466A - Vacinas de tumores e processo para a sua preparação - Google Patents

Vacinas de tumores e processo para a sua preparação

Info

Publication number
BR9611466A
BR9611466A BR9611466A BR9611466A BR9611466A BR 9611466 A BR9611466 A BR 9611466A BR 9611466 A BR9611466 A BR 9611466A BR 9611466 A BR9611466 A BR 9611466A BR 9611466 A BR9611466 A BR 9611466A
Authority
BR
Brazil
Prior art keywords
preparation
tumor vaccines
vaccines
tumor
Prior art date
Application number
BR9611466A
Other languages
English (en)
Inventor
Walter Schmidt
Max Birnstiel
Tamas Schweighoffer
Peter Steinlein
Michael Buschle
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19543649A external-priority patent/DE19543649C2/de
Priority claimed from DE19607044A external-priority patent/DE19607044A1/de
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BR9611466A publication Critical patent/BR9611466A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR9611466A 1995-11-23 1996-11-21 Vacinas de tumores e processo para a sua preparação BR9611466A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19543649A DE19543649C2 (de) 1995-11-23 1995-11-23 Tumorvakzine und Verfahren zu ihrer Herstellung
DE19607044A DE19607044A1 (de) 1996-02-24 1996-02-24 Tumorvakzine und Verfahren zu ihrer Herstellung
PCT/EP1996/005126 WO1997019169A1 (de) 1995-11-23 1996-11-21 Tumorvakzine und verfahren zu ihrer herstellung

Publications (1)

Publication Number Publication Date
BR9611466A true BR9611466A (pt) 1999-05-18

Family

ID=26020603

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9611466A BR9611466A (pt) 1995-11-23 1996-11-21 Vacinas de tumores e processo para a sua preparação

Country Status (24)

Country Link
US (1) US20020085997A1 (pt)
EP (1) EP0866851A1 (pt)
JP (1) JP2000502052A (pt)
KR (1) KR19990067653A (pt)
CN (1) CN1202931A (pt)
AR (1) AR004341A1 (pt)
AU (1) AU720131B2 (pt)
BG (1) BG62999B1 (pt)
BR (1) BR9611466A (pt)
CA (1) CA2238176A1 (pt)
CO (1) CO4520254A1 (pt)
CZ (1) CZ158998A3 (pt)
EE (1) EE03778B1 (pt)
HU (1) HUP0000318A3 (pt)
NO (1) NO982329D0 (pt)
NZ (1) NZ322910A (pt)
PL (1) PL188537B1 (pt)
RO (1) RO115275B1 (pt)
RU (1) RU2206329C2 (pt)
SK (1) SK66998A3 (pt)
TR (1) TR199800912T2 (pt)
TW (1) TW514530B (pt)
UY (2) UY24367A1 (pt)
WO (1) WO1997019169A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
US6187307B1 (en) * 1997-01-31 2001-02-13 Research Corporation Technologies, Inc. Cancer immunotherapy with semi-allogeneic cells
DK0904786T3 (da) * 1997-08-22 2005-03-21 Science Park Raf S P A Tumorvaccination under anvendelse af autologe eller HLA-relaterede antigenpræsenterende celler (APC) transduceret med et tumorantigen og et fremmed antigen, som kan fremkalde en immunreaktion
US7014848B1 (en) 1998-03-20 2006-03-21 Genzyme Corporation Enhanced anti-tumor immunity
WO1999047687A1 (en) * 1998-03-20 1999-09-23 Genzyme Corporation Enhanced anti-tumor immunity
FR2807661A1 (fr) * 2000-04-14 2001-10-19 Univ Nantes Agent et procede pour la simulation de lymphocytes t specifiques et lymphocytes t obtenus
US20060035291A1 (en) * 2001-09-18 2006-02-16 Kyogo Itoh Method of detecting cellular immunity and application thereof to drugs
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
CN1315536C (zh) * 2002-09-13 2007-05-16 李进 肿瘤抗原疫苗及其制备方法和疫苗组合物
GB0224442D0 (en) 2002-10-21 2002-11-27 Molmed Spa A delivery system
ATE475430T1 (de) * 2003-08-25 2010-08-15 Univax Llc Präventive krebsvakzine auf basis des boris (brother of regulator of imprinted sites) moleküls
US7674456B2 (en) * 2004-06-14 2010-03-09 Charles Wiseman Breast cancer cell lines and uses thereof
EP1871166A4 (en) 2005-03-29 2008-11-12 Univ Illinois VACCINES AGAINST CANCER AND THERAPEUTIC METHODS
DK1806359T3 (da) * 2005-09-05 2010-06-14 Immatics Biotechnologies Gmbh Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US8765148B2 (en) 2010-02-19 2014-07-01 Valneva Austria Gmbh 1C31 nanoparticles
WO2014012051A1 (en) * 2012-07-12 2014-01-16 Persimmune, Inc. Personalized cancer vaccines and adoptive immune cell therapies
JP6710004B2 (ja) 2016-03-15 2020-06-17 Ｒｅｐｅｒｔｏｉｒｅ Ｇｅｎｅｓｉｓ株式会社 免疫療法のためのモニタリングまたは診断ならびに治療剤の設計
JP2020518648A (ja) 2017-05-08 2020-06-25 グリットストーン オンコロジー インコーポレイテッド アルファウイルス新生抗原ベクター
SG11202113187WA (en) 2019-05-30 2021-12-30 Gritstone Bio Inc Modified adenoviruses
WO2022032196A2 (en) 2020-08-06 2022-02-10 Gritstone Bio, Inc. Multiepitope vaccine cassettes
EP4304615A1 (en) * 2021-03-12 2024-01-17 T-Cure Bioscience, Inc. Methods of enhancing diversity of hla haplotype expression in tumors to broaden tumor cell susceptibility to tcr-t therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235525B1 (en) * 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
EP0569678A3 (en) * 1992-03-13 1994-10-26 Yeda Res & Dev Double transfectants of MHC genes as cellular vaccines for immunoprevention of tumor metastasis.

Also Published As

Publication number Publication date
CO4520254A1 (es) 1997-10-15
UY24367A1 (es) 2000-10-31
HUP0000318A2 (hu) 2000-06-28
KR19990067653A (ko) 1999-08-25
SK66998A3 (en) 1998-12-02
NO982329D0 (no) 1998-05-22
CN1202931A (zh) 1998-12-23
CZ158998A3 (cs) 1999-06-16
BG62999B1 (bg) 2001-01-31
UY24430A1 (es) 1997-07-01
AU7694796A (en) 1997-06-11
US20020085997A1 (en) 2002-07-04
NZ322910A (en) 2000-05-26
EP0866851A1 (de) 1998-09-30
PL188537B1 (pl) 2005-02-28
TW514530B (en) 2002-12-21
AU720131B2 (en) 2000-05-25
AR004341A1 (es) 1998-11-04
CA2238176A1 (en) 1997-05-29
JP2000502052A (ja) 2000-02-22
TR199800912T2 (xx) 1998-08-21
HUP0000318A3 (en) 2002-02-28
EE9800161A (et) 1998-12-15
BG102439A (en) 1999-01-29
RO115275B1 (ro) 1999-12-30
RU2206329C2 (ru) 2003-06-20
EE03778B1 (et) 2002-06-17
PL326756A1 (en) 1998-10-26
WO1997019169A1 (de) 1997-05-29

Similar Documents

Publication Publication Date Title
BR9611466A (pt) Vacinas de tumores e processo para a sua preparação
PT750907E (pt) Formulacoes de vacinas estaveis para administracao parenterica metodo para a sua utilizacao e processo para a sua preparacao
PT909327E (pt) Eritromicinas e processo para a sua preparacao
PT799866E (pt) Negro-de-fumo e processo para a sua preparacao
BR9505940A (pt) Comprimido mastigável e processo para sua preparação
PT845505E (pt) Pigmentos esfericos processo para a sua preparacao e sua utilizacao
BR9505527A (pt) Catalisador para a desidratação de c6-a c15-parafinas e processo para sua preparação
BR9605919A (pt) Catalisadores e processos para sua preparação
BR9408463A (pt) Novos derivados de ginkgolide e processo para sua preparação
BR9002288A (pt) Copolimeros hidrossoluveis,processo para a sua obtencao e sua utilizacao
BR9000489A (pt) Conecao de mangueira e processo para a sua fixacao
BR9600148A (pt) Quinazolinonas 2,8-dissubstituídas processo para sua preparação medicamentos e uso
PT770615E (pt) Processo para a preparacao de di-haloazolopirimidinas
BR9606396A (pt) Derivados de camptotecin substituídos e processo para sua preparação
PT100316A (pt) Anticoagulantes e processo para a sua preparacao
BR9606782A (pt) Processo para preparar ciclopilacetileno
BR9102794A (pt) Processo para a obtencao de tantalo e niobio
BR9602983A (pt) Gel e processo para sua preparação
BR9401642A (pt) Restaurador de cabelos e processo para sua preparação
BR9300739A (pt) Processo hidrometalurgico para a obtencao de tantalo e niobio
PT900253E (pt) Composicoes de betume e um processo para a sua preparacao
BR9600149A (pt) 2-(2-N-alcoxifenil)-purin-6-onas 9-substituídas processo para sua preparação medicamantos e uso
BR9101488A (pt) Preparados de lipossomas,sua utilizacao e processo para a sua producao
PT1015421E (pt) Novos derivados de fenilamidina processo para a sua preparacao e sua utilizacao como medicamentos
BR9703634A (pt) Poliamidoaminas ligadas silila e processo para a sua preparação

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B15K Others concerning applications: alteration of classification

Ipc: C07K 7/06 (2006.01), A61K 39/00 (2006.0